Alginate encapsulation for bupivacaine delivery and mesenchymal stromal cell immunomodulatory cotherapy
| Autor: | Palangat Radhakrishnan, Joel Yarmush, Charles P. Rabolli, Devasena Manchikalapati, Hattiyangangadi Kamath, Joseph SchianodiCola, Mollie S. Davis, Isabel Perez, Ileana Marrero-Berrios, Rene S. Schloss |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Bupivacaine Stromal cell business.industry medicine.medical_treatment Immunology Mesenchymal stem cell Inflammation Pharmacology 3. Good health 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Bolus (medicine) Cytokine 030220 oncology & carcinogenesis medicine Immunology and Allergy Tumor necrosis factor alpha medicine.symptom Prostaglandin E2 business medicine.drug |
| Zdroj: | Journal of Inflammation Research. 12:87-97 |
| ISSN: | 1178-7031 |
| Popis: | Purpose Mesenchymal stromal cells (MSCs) are used to treat various inflammatory conditions. In parallel, to mitigate pain associated with inflammation, analgesics or opioids are prescribed, often with significant side effects. Local anesthetics (LAs) offer a promising alternative to these medications. However, their short duration and negative effects on anti-inflammatory MSCs have limited their therapeutic effectiveness. To mitigate these negative effects and to move toward developing a cotherapy, we engineered a sustained release bupivacaine alginate-liposomal construct that enables up to 4 days of LA release. By encapsulating MSC in alginate (eMSC), we demonstrate that we can further increase drug concentration to clinically relevant levels, without compromising eMSC viability or anti-inflammatory function. Materials and methods MSCs were freely cultured or encapsulated in alginate microspheres ± TNFα/IFN-γ and were left untreated or dosed with bolus, liposomal, or construct bupivacaine. After 24, 48, and 96 hours, the profiles were assessed to quantify secretory function associated with LA-MSC interactions. To approximate LA exposure over time, a MATLAB model was generated. Results eMSCs secrete similar levels of IL-6 and prostaglandin E2 (PGE2) regardless of LA modality, whereas free MSCs secrete larger amounts of IL-6 and lower amounts of anti-inflammatory PGE2. Modeling the system indicated that higher doses of LA can be used in conjunction with eMSC while retaining eMSC viability and function. In general, eMSC treated with higher doses of LA secreted similar or higher levels of immunomodulatory cytokines. Conclusion eMSCs, but not free MSC, are protected from LA, regardless of LA modality. Increasing the LA concentration may promote longer and stronger pain mitigation while the protected eMSCs secrete similar, if not higher, immunomodulatory cytokine levels. Therefore, we have developed an approach, using eMSC and the LA construct that can potentially be used to reduce pain as well as improve MSC anti-inflammatory function. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|